ICH Guidelines Overview

Detected March 13th, 2026

Summary

The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) provides guidelines across quality, safety, efficacy, and multidisciplinary areas. These guidelines aim to harmonize technical requirements for pharmaceutical registration globally.

View original document View source feed page

What changed

This document serves as an overview of the International Council for Harmonisation (ICH) guidelines, categorizing them into Quality, Safety, Efficacy, and Multidisciplinary areas. It highlights key achievements within each category, such as advancements in stability studies, impurity testing thresholds, non-clinical testing strategies for QT interval prolongation, clinical trial design, and the development of common technical documents and medical terminology.

These guidelines are non-binding but represent a global standard for pharmaceutical development and regulation. Pharmaceutical companies, drug manufacturers, and healthcare providers involved in the development, testing, and registration of medicines should consult these guidelines to ensure compliance with harmonized international standards. While no specific compliance deadlines are mentioned, adherence is crucial for efficient global drug approval processes.

What to do next

Review ICH Quality guidelines for stability studies and impurity testing.
Consult ICH Safety guidelines for drug risk assessment, including QT interval liability.
Examine ICH Efficacy guidelines for clinical trial design and reporting standards.

Source document (simplified)

Home \ ICH Guidelines \ All Guidelines

ICH Guidelines

The ICH topics are divided into the four categories below and ICH topic codes are assigned according to these categories.

Quality Guidelines

Harmonisation achievements in the Quality area include pivotal milestones such as the conduct of stability studies, defining relevant thresholds for impurities testing and a more flexible approach to pharmaceutical quality based on Good Manufacturing Practice (GMP) risk management.

Safety Guidelines

ICH has produced a comprehensive set of safety Guidelines to uncover potential risks like carcinogenicity, genotoxicity and reprotoxicity. A recent breakthrough has been a non-clinical testing strategy for assessing the QT interval prolongation liability: the single most important cause of drug withdrawals in recent years.

Efficacy Guidelines

The work carried out by ICH under the Efficacy heading is concerned with the design, conduct, safety and reporting of clinical trials. It also covers novel types of medicines derived from biotechnological processes and the use of pharmacogenetics/genomics techniques to produce better targeted medicines.

Multidisciplinary Guidelines

Those are the cross-cutting topics which do not fit uniquely into one of the Quality, Safety and Efficacy categories. It includes the ICH medical terminology (MedDRA), the Common Technical Document (CTD) and the development of Electronic Standards for the Transfer of Regulatory Information (ESTRI).